Celestra Inc
352770
Company Profile
Business description
Celestra Inc is a biotechnology company. The company provides early diagnosis of cancer/diseases based on genome and pursues to overcome aging and diseases through liquid biopsy and Multi-Omics technology. It offers a genome-based, early cancer diagnostic service through technology for multi-omics analysis and simultaneous detection of CTC and cfDNA in the blood based.
Contact
Building 110, UNIST, 50
Suite 301-3, UNIST-gil, Eonyang-eup, Ulju-gun
Ulsan44919
KORT: +82 7082866966
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
48
Stocks News & Analysis
stocks
Going into earnings, is Netflix stock a buy, a sell, or fairly valued?
Watching sales growth and the potential for margin expansion, here’s what we think of Netflix stock.
stocks
Bapcor is paying for the sins of its past
Shares plunged over 17% after reporting disappointing results.
stocks
Overvalued ASX share as market underestimates downside risks
Growth outlook solid, but upside more than priced in.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,390.10 | 16.40 | 0.17% |
| CAC 40 | 8,224.55 | 18.48 | 0.23% |
| DAX 40 | 24,244.32 | 14.48 | -0.06% |
| Dow JONES (US) | 46,706.58 | 515.97 | 1.12% |
| FTSE 100 | 9,423.83 | 20.26 | 0.22% |
| HKSE | 26,027.55 | 168.72 | 0.65% |
| NASDAQ | 22,990.54 | 310.57 | 1.37% |
| Nikkei 225 | 49,316.06 | 130.56 | 0.27% |
| NZX 50 Index | 13,377.85 | 32.89 | 0.25% |
| S&P 500 | 6,735.13 | 71.12 | 1.07% |
| S&P/ASX 200 | 9,094.70 | 18.80 | 0.21% |
| SSE Composite Index | 3,916.33 | 52.44 | 1.36% |